Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21185808rdf:typepubmed:Citationlld:pubmed
pubmed-article:21185808lifeskim:mentionsumls-concept:C0003015lld:lifeskim
pubmed-article:21185808lifeskim:mentionsumls-concept:C0042401lld:lifeskim
pubmed-article:21185808lifeskim:mentionsumls-concept:C0006100lld:lifeskim
pubmed-article:21185808lifeskim:mentionsumls-concept:C0034826lld:lifeskim
pubmed-article:21185808lifeskim:mentionsumls-concept:C0033414lld:lifeskim
pubmed-article:21185808lifeskim:mentionsumls-concept:C0205296lld:lifeskim
pubmed-article:21185808lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:21185808pubmed:issue6lld:pubmed
pubmed-article:21185808pubmed:dateCreated2011-2-21lld:pubmed
pubmed-article:21185808pubmed:abstractTextBradykinin-potentiating peptides (BPPs) or proline-rich oligopeptides (PROs) isolated from the venom glands of Bothrops jararaca (Bj) were the first natural inhibitors of the angiotensin-converting enzyme (ACE) described. Bj-PRO-5a (<EKWAP), a member of this structurally related peptide family, was essential for the development of captopril, the first site-directed ACE inhibitor used for the treatment of human hypertension. Nowadays, more Bj-PROs have been identified with higher ACE inhibition potency compared to Bj-PRO-5a. However, despite its modest inhibitory effect of ACE inhibition, Bj-PRO-5a reveals strong bradykinin-potentiating activity, suggesting the participation of other mechanisms for this peptide. In the present study, we have shown that Bj-PRO-5a induced nitric oxide (NO) production depended on muscarinic acetylcholine receptor M1 subtype (mAchR-M1) and bradykinin B? receptor activation, as measured by a chemiluminescence assay using a NO analyzer. Intravital microscopy based on transillumination of mice cremaster muscle also showed that both bradykinin B? receptor and mAchR-M1 contributed to the vasodilatation induced by Bj-PRO-5a. Moreover, Bj-PRO-5a-mediated vasodilatation was completely blocked in the presence of a NO synthase inhibitor. The importance of this work lies in the definition of novel targets for Bj-PRO-5a in addition to ACE, the structural model for captopril development.lld:pubmed
pubmed-article:21185808pubmed:languageenglld:pubmed
pubmed-article:21185808pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21185808pubmed:citationSubsetIMlld:pubmed
pubmed-article:21185808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21185808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21185808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21185808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21185808pubmed:statusMEDLINElld:pubmed
pubmed-article:21185808pubmed:monthMarlld:pubmed
pubmed-article:21185808pubmed:issn1873-2968lld:pubmed
pubmed-article:21185808pubmed:authorpubmed-author:UlrichHHlld:pubmed
pubmed-article:21185808pubmed:authorpubmed-author:LameyGGlld:pubmed
pubmed-article:21185808pubmed:authorpubmed-author:Lopes-Ferreir...lld:pubmed
pubmed-article:21185808pubmed:authorpubmed-author:HayashiM A...lld:pubmed
pubmed-article:21185808pubmed:authorpubmed-author:CamargoA C...lld:pubmed
pubmed-article:21185808pubmed:authorpubmed-author:MoraisK L PKLlld:pubmed
pubmed-article:21185808pubmed:authorpubmed-author:BruniF MFMlld:pubmed
pubmed-article:21185808pubmed:copyrightInfoCopyright © 2011 Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:21185808pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21185808pubmed:day15lld:pubmed
pubmed-article:21185808pubmed:volume81lld:pubmed
pubmed-article:21185808pubmed:ownerNLMlld:pubmed
pubmed-article:21185808pubmed:authorsCompleteYlld:pubmed
pubmed-article:21185808pubmed:pagination736-42lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:meshHeadingpubmed-meshheading:21185808...lld:pubmed
pubmed-article:21185808pubmed:year2011lld:pubmed
pubmed-article:21185808pubmed:articleTitleBj-PRO-5a, a natural angiotensin-converting enzyme inhibitor, promotes vasodilatation mediated by both bradykinin B?and M1 muscarinic acetylcholine receptors.lld:pubmed
pubmed-article:21185808pubmed:affiliationCenter for Applied Toxinology CAT-CEPID, Instituto Butantan, SP, Brazil.lld:pubmed
pubmed-article:21185808pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21185808pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:21185808pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed